JP2013209405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013209405A5 JP2013209405A5 JP2013108533A JP2013108533A JP2013209405A5 JP 2013209405 A5 JP2013209405 A5 JP 2013209405A5 JP 2013108533 A JP2013108533 A JP 2013108533A JP 2013108533 A JP2013108533 A JP 2013108533A JP 2013209405 A5 JP2013209405 A5 JP 2013209405A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- independently
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 75
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 20
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 10
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- -1 3,5-di-substituted phenyl Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 2
- 101100273648 Mus musculus Ccna2 gene Proteins 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 *C(*1CCCCC1)=O Chemical compound *C(*1CCCCC1)=O 0.000 description 2
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31882410P | 2010-03-30 | 2010-03-30 | |
| US61/318,824 | 2010-03-30 | ||
| US32157310P | 2010-04-07 | 2010-04-07 | |
| US61/321,573 | 2010-04-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538161A Division JP5281718B2 (ja) | 2010-03-30 | 2011-03-28 | 非ヌクレオシド逆転写酵素阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013209405A JP2013209405A (ja) | 2013-10-10 |
| JP2013209405A5 true JP2013209405A5 (enExample) | 2015-09-17 |
| JP5886790B2 JP5886790B2 (ja) | 2016-03-16 |
Family
ID=44710363
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538161A Active JP5281718B2 (ja) | 2010-03-30 | 2011-03-28 | 非ヌクレオシド逆転写酵素阻害剤 |
| JP2013108533A Expired - Fee Related JP5886790B2 (ja) | 2010-03-30 | 2013-05-23 | 非ヌクレオシド逆転写酵素阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538161A Active JP5281718B2 (ja) | 2010-03-30 | 2011-03-28 | 非ヌクレオシド逆転写酵素阻害剤 |
Country Status (44)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102971308B (zh) * | 2010-03-30 | 2015-02-04 | 默克加拿大有限公司 | 非核苷类逆转录酶抑制剂 |
| US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
| EP2900240B1 (en) * | 2012-09-26 | 2020-01-08 | Merck Sharp & Dohme Corp. | Crystalline form of a reverse transcriptase inhibitor |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| MX355439B (es) * | 2012-12-05 | 2018-04-18 | Merck Sharp & Dohme | Proceso para preparar inhibidores de la transcriptasa inversa. |
| MX375870B (es) * | 2013-11-22 | 2025-03-07 | Merck Sharp & Dohme Llc | Composicion de un inhibidor de la transcriptasa inversa sin nucleosido. |
| CA2930585A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Process for making reverse transcriptase inhibitors |
| RU2693622C2 (ru) | 2014-04-01 | 2019-07-03 | Мерк Шарп И Доум Корп. | Пролекарственные средства ингибиторов обратной транскриптазы вич |
| EP3760208B1 (en) | 2014-06-25 | 2024-05-29 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| RU2736941C2 (ru) | 2015-12-02 | 2020-11-23 | Мерк Шарп энд Доум Корп. | Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин |
| WO2018175271A1 (en) * | 2017-03-24 | 2018-09-27 | Merck Sharp & Dohme Corp. | Formulation for parenteral administration |
| JP2020517633A (ja) | 2017-04-18 | 2020-06-18 | シプラ・リミテッド | レトロウイルス感染の治療に用いる併用療法 |
| US20210213041A1 (en) | 2018-02-06 | 2021-07-15 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
| US12005072B2 (en) | 2018-07-17 | 2024-06-11 | Merck Sharp & Dohme Llc | HIV drug combination for increasing barrier against resistance |
| MA54549A (fr) | 2018-12-18 | 2022-03-30 | Merck Sharp & Dohme | Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih |
| CN110801455B (zh) * | 2019-11-12 | 2020-06-02 | 河北医科大学第二医院 | 用于治疗mrsa的药物组合物及其应用 |
| CN114163309B (zh) * | 2021-12-27 | 2023-04-25 | 甘肃皓天医药科技有限责任公司 | 一种多拉韦林中间体的制备方法 |
| CN114349690B (zh) * | 2022-02-15 | 2023-04-25 | 甘肃皓天医药科技有限责任公司 | 一种多拉韦林中间体合成方法 |
| CN116903590A (zh) * | 2023-06-06 | 2023-10-20 | 延边大学 | 一种含杂环结构的吡啶酮类化合物及其制备方法和用途 |
| CN120157613A (zh) * | 2023-12-15 | 2025-06-17 | 山东诚创蓝海医药科技有限公司 | 多拉韦林中间体及其应用和合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904045D0 (sv) | 1999-11-09 | 1999-11-09 | Astra Ab | Compounds |
| TW200423930A (en) * | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| TW200505441A (en) * | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
| EP1608629A1 (en) | 2003-03-24 | 2005-12-28 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| US7166738B2 (en) | 2004-04-23 | 2007-01-23 | Roche Palo Alto Llc | Non-nucleoside reverse transcriptase inhibitors |
| DK1742908T3 (da) | 2004-04-23 | 2010-01-18 | Hoffmann La Roche | Ikke nukleosid revers transkriptase inhibitorer |
| EP1831157A2 (en) | 2004-12-22 | 2007-09-12 | Pfizer Limited | Nonnucleoside inhibitors of hiv-1 reverse transcriptase |
| AR057455A1 (es) | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| BRPI0617720A2 (pt) | 2005-10-19 | 2011-08-02 | Hoffmann La Roche | compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém |
| ES2320042T3 (es) | 2005-10-19 | 2009-05-18 | F. Hoffmann-La Roche Ag | Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida. |
| TW200831085A (en) | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
| AU2008326784B2 (en) | 2007-11-20 | 2014-04-24 | Merck Sharp & Dohme Corp. | Non-nucleoside reverse transcriptase inhibitors |
| CN102971308B (zh) * | 2010-03-30 | 2015-02-04 | 默克加拿大有限公司 | 非核苷类逆转录酶抑制剂 |
-
2011
- 2011-03-28 CN CN201180018074.2A patent/CN102971308B/zh active Active
- 2011-03-28 KR KR1020127025733A patent/KR101421861B1/ko active Active
- 2011-03-28 HR HRP20150427TT patent/HRP20150427T1/hr unknown
- 2011-03-28 EA EA201290976A patent/EA024804B1/ru active Protection Beyond IP Right Term
- 2011-03-28 HU HUE11761856A patent/HUE025336T2/en unknown
- 2011-03-28 PL PL11761856T patent/PL2552902T3/pl unknown
- 2011-03-28 PE PE2012001823A patent/PE20130158A1/es active IP Right Grant
- 2011-03-28 MA MA35324A patent/MA34170B1/fr unknown
- 2011-03-28 NZ NZ602670A patent/NZ602670A/en unknown
- 2011-03-28 DK DK11761856.1T patent/DK2552902T3/en active
- 2011-03-28 US US13/073,631 patent/US8486975B2/en active Active
- 2011-03-28 ES ES15157348.2T patent/ES2609636T3/es active Active
- 2011-03-28 RS RS20161093A patent/RS55505B1/sr unknown
- 2011-03-28 GE GEAP201112882A patent/GEP20156368B/en unknown
- 2011-03-28 PT PT117618561T patent/PT2552902E/pt unknown
- 2011-03-28 EP EP11761856.1A patent/EP2552902B1/en active Active
- 2011-03-28 EP EP15157348.2A patent/EP2924034B1/en active Active
- 2011-03-28 ME MEP-2016-282A patent/ME02570B/me unknown
- 2011-03-28 HU HUE15157348A patent/HUE031785T2/en unknown
- 2011-03-28 CA CA2794377A patent/CA2794377C/en active Active
- 2011-03-28 JP JP2012538161A patent/JP5281718B2/ja active Active
- 2011-03-28 WO PCT/CA2011/000320 patent/WO2011120133A1/en not_active Ceased
- 2011-03-28 ES ES11761856.1T patent/ES2536295T3/es active Active
- 2011-03-28 RS RS20150340A patent/RS54017B1/sr unknown
- 2011-03-28 PH PH1/2012/501923A patent/PH12012501923A1/en unknown
- 2011-03-28 MY MYPI2012004342A patent/MY163979A/en unknown
- 2011-03-28 SG SG2012072401A patent/SG184347A1/en unknown
- 2011-03-28 DK DK15157348.2T patent/DK2924034T3/en active
- 2011-03-28 SI SI201131054A patent/SI2924034T1/sl unknown
- 2011-03-28 AU AU2011235568A patent/AU2011235568B2/en active Active
- 2011-03-28 ME MEP-2015-76A patent/ME02181B/me unknown
- 2011-03-28 LT LTEP15157348.2T patent/LT2924034T/lt unknown
- 2011-03-28 SI SI201130491T patent/SI2552902T1/sl unknown
- 2011-03-28 BR BR112012024691-7A patent/BR112012024691B1/pt active IP Right Grant
- 2011-03-28 MX MX2012011379A patent/MX2012011379A/es active IP Right Grant
- 2011-03-28 PT PT151573482T patent/PT2924034T/pt unknown
- 2011-03-28 PL PL15157348T patent/PL2924034T3/pl unknown
- 2011-03-29 AR ARP110101028A patent/AR080859A1/es active IP Right Grant
- 2011-03-29 TW TW100110833A patent/TWI458719B/zh active
-
2012
- 2012-09-20 TN TNP2012000455A patent/TN2012000455A1/en unknown
- 2012-09-20 IL IL222030A patent/IL222030A/en active Protection Beyond IP Right Term
- 2012-09-27 HN HN2012002039A patent/HN2012002039A/es unknown
- 2012-09-28 NI NI201200146A patent/NI201200146A/es unknown
- 2012-09-28 DO DO2012000256A patent/DOP2012000256A/es unknown
- 2012-09-28 CL CL2012002744A patent/CL2012002744A1/es unknown
- 2012-10-01 EC ECSP12012201 patent/ECSP12012201A/es unknown
- 2012-10-01 CR CR20120503A patent/CR20120503A/es unknown
- 2012-10-01 CO CO12171897A patent/CO6630126A2/es active IP Right Grant
-
2013
- 2013-05-23 JP JP2013108533A patent/JP5886790B2/ja not_active Expired - Fee Related
- 2013-07-03 US US13/934,633 patent/US20130296382A1/en not_active Abandoned
-
2014
- 2014-06-23 IL IL233334A patent/IL233334A/en active IP Right Grant
-
2016
- 2016-12-09 HR HRP20161680TT patent/HRP20161680T1/hr unknown
-
2017
- 2017-01-25 CY CY20171100114T patent/CY1118774T1/el unknown
-
2019
- 2019-04-09 HU HUS1900021C patent/HUS1900021I1/hu unknown
- 2019-04-09 HU HUS1900022C patent/HUS1900022I1/hu unknown
- 2019-04-11 LT LTPA2019507C patent/LTC2924034I2/lt unknown
- 2019-04-11 LT LTPA2019506 patent/LTC2552902I2/lt unknown
- 2019-04-16 NL NL300980C patent/NL300980I2/nl unknown
- 2019-04-17 LU LU00114C patent/LUC00114I2/fr unknown
- 2019-04-17 LU LU00113C patent/LUC00113I9/fr unknown
- 2019-04-17 FI FIC20190021C patent/FIC20190021I1/fi unknown
- 2019-04-24 NO NO2019019C patent/NO2019019I1/no unknown
- 2019-04-24 NO NO2019018C patent/NO2019018I1/no unknown
- 2019-05-16 CY CY2019025C patent/CY2019025I1/el unknown
- 2019-05-16 CY CY2019026C patent/CY2019026I1/el unknown